UCB SA (UCB.BR) Stock Fundamental Analysis
EBR:UCB - Euronext Brussels - BE0003739530 - Common Stock - Currency: EUR
UCB gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 51 industry peers in the Pharmaceuticals industry. UCB has an average financial health and profitability rating. UCB is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
UCB had positive earnings in the past year.
In the past year UCB had a positive cash flow from operations.
In the past 5 years UCB has always been profitable.
UCB had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
The Return On Assets of UCB (6.14%) is comparable to the rest of the industry.
Looking at the Return On Equity, with a value of 10.62%, UCB is in line with its industry, outperforming 54.90% of the companies in the same industry.
UCB has a Return On Invested Capital of 8.79%. This is comparable to the rest of the industry: UCB outperforms 52.94% of its industry peers.
The Average Return On Invested Capital over the past 3 years for UCB is significantly below the industry average of 15.16%.
The 3 year average ROIC (4.35%) for UCB is below the current ROIC(8.79%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.14% | ||
| ROE | 10.62% | ||
| ROIC | 8.79% |
ROA(3y)3.66%
ROA(5y)4.78%
ROE(3y)6.35%
ROE(5y)8.35%
ROIC(3y)4.35%
ROIC(5y)6.33%
1.3 Margins
Looking at the Profit Margin, with a value of 17.31%, UCB is in the better half of the industry, outperforming 68.63% of the companies in the same industry.
UCB's Profit Margin has been stable in the last couple of years.
UCB has a Operating Margin of 23.31%. This is comparable to the rest of the industry: UCB outperforms 58.82% of its industry peers.
UCB's Operating Margin has declined in the last couple of years.
UCB has a Gross Margin (71.52%) which is in line with its industry peers.
UCB's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 23.31% | ||
| PM (TTM) | 17.31% | ||
| GM | 71.52% |
OM growth 3Y-15.5%
OM growth 5Y-9.39%
PM growth 3Y-1.86%
PM growth 5Y1.44%
GM growth 3Y-1.62%
GM growth 5Y-0.73%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), UCB is creating some value.
Compared to 1 year ago, UCB has about the same amount of shares outstanding.
Compared to 5 years ago, UCB has more shares outstanding
UCB has a better debt/assets ratio than last year.
2.2 Solvency
UCB has an Altman-Z score of 4.27. This indicates that UCB is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 4.27, UCB is in the better half of the industry, outperforming 66.67% of the companies in the same industry.
UCB has a debt to FCF ratio of 3.29. This is a good value and a sign of high solvency as UCB would need 3.29 years to pay back of all of its debts.
The Debt to FCF ratio of UCB (3.29) is better than 64.71% of its industry peers.
UCB has a Debt/Equity ratio of 0.30. This is a healthy value indicating a solid balance between debt and equity.
UCB has a Debt to Equity ratio of 0.30. This is in the better half of the industry: UCB outperforms 64.71% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.3 | ||
| Debt/FCF | 3.29 | ||
| Altman-Z | 4.27 |
ROIC/WACC1.17
WACC7.48%
2.3 Liquidity
UCB has a Current Ratio of 1.36. This is a normal value and indicates that UCB is financially healthy and should not expect problems in meeting its short term obligations.
UCB has a Current ratio (1.36) which is in line with its industry peers.
UCB has a Quick Ratio of 1.36. This is a bad value and indicates that UCB is not financially healthy enough and could expect problems in meeting its short term obligations.
UCB has a Quick ratio of 0.99. This is comparable to the rest of the industry: UCB outperforms 56.86% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.36 | ||
| Quick Ratio | 0.99 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 18.57% over the past year.
UCB shows a decrease in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -0.86% yearly.
UCB shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 17.14%.
Measured over the past years, UCB shows a small growth in Revenue. The Revenue has been growing by 4.60% on average per year.
EPS 1Y (TTM)18.57%
EPS 3Y-8.45%
EPS 5Y-0.86%
EPS Q2Q%84.08%
Revenue 1Y (TTM)17.14%
Revenue growth 3Y2.12%
Revenue growth 5Y4.6%
Sales Q2Q%26.21%
3.2 Future
Based on estimates for the next years, UCB will show a very strong growth in Earnings Per Share. The EPS will grow by 26.60% on average per year.
UCB is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 10.98% yearly.
EPS Next Y48.96%
EPS Next 2Y37.44%
EPS Next 3Y34.53%
EPS Next 5Y26.6%
Revenue Next Year15.28%
Revenue Next 2Y14.13%
Revenue Next 3Y13.53%
Revenue Next 5Y10.98%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 37.05, UCB can be considered very expensive at the moment.
UCB's Price/Earnings ratio is a bit more expensive when compared to the industry. UCB is more expensive than 60.78% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 26.48. UCB is valued slightly more expensive when compared to this.
The Price/Forward Earnings ratio is 24.87, which indicates a rather expensive current valuation of UCB.
Compared to the rest of the industry, the Price/Forward Earnings ratio of UCB indicates a slightly more expensive valuation: UCB is more expensive than 62.75% of the companies listed in the same industry.
UCB's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 34.04.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 37.05 | ||
| Fwd PE | 24.87 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of UCB is on the same level as its industry peers.
UCB's Price/Free Cash Flow is on the same level as the industry average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 39.01 | ||
| EV/EBITDA | 17.71 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as UCB's earnings are expected to grow with 34.53% in the coming years.
PEG (NY)0.76
PEG (5Y)N/A
EPS Next 2Y37.44%
EPS Next 3Y34.53%
5. Dividend
5.1 Amount
With a yearly dividend of 0.51%, UCB is not a good candidate for dividend investing.
UCB's Dividend Yield is comparable with the industry average which is at 3.14.
With a Dividend Yield of 0.51, UCB pays less dividend than the S&P500 average, which is at 2.40.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.51% |
5.2 History
The dividend of UCB has a limited annual growth rate of 2.46%.
Dividend Growth(5Y)2.46%
Div Incr Years6
Div Non Decr Years6
5.3 Sustainability
UCB pays out 24.32% of its income as dividend. This is a sustainable payout ratio.
The dividend of UCB is growing, but earnings are growing more, so the dividend growth is sustainable.
DP24.32%
EPS Next 2Y37.44%
EPS Next 3Y34.53%
EBR:UCB (8/8/2025, 7:00:00 PM)
184.5
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners38.65%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap35.89B
Analysts75.83
Price Target216.18 (17.17%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.51% |
Yearly Dividend1.36
Dividend Growth(5Y)2.46%
DP24.32%
Div Incr Years6
Div Non Decr Years6
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)2.07%
PT rev (3m)2.2%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-1.18%
Revenue NY rev (3m)-1.14%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 37.05 | ||
| Fwd PE | 24.87 | ||
| P/S | 5.83 | ||
| P/FCF | 39.01 | ||
| P/OCF | 28.89 | ||
| P/B | 3.58 | ||
| P/tB | 73.99 | ||
| EV/EBITDA | 17.71 |
EPS(TTM)4.98
EY2.7%
EPS(NY)7.42
Fwd EY4.02%
FCF(TTM)4.73
FCFY2.56%
OCF(TTM)6.39
OCFY3.46%
SpS31.63
BVpS51.56
TBVpS2.49
PEG (NY)0.76
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.14% | ||
| ROE | 10.62% | ||
| ROCE | 10.38% | ||
| ROIC | 8.79% | ||
| ROICexc | 10.16% | ||
| ROICexgc | 50.51% | ||
| OM | 23.31% | ||
| PM (TTM) | 17.31% | ||
| GM | 71.52% | ||
| FCFM | 14.95% |
ROA(3y)3.66%
ROA(5y)4.78%
ROE(3y)6.35%
ROE(5y)8.35%
ROIC(3y)4.35%
ROIC(5y)6.33%
ROICexc(3y)4.85%
ROICexc(5y)7.22%
ROICexgc(3y)28.31%
ROICexgc(5y)48.18%
ROCE(3y)5.15%
ROCE(5y)7.49%
ROICexcg growth 3Y-25.87%
ROICexcg growth 5Y-16.2%
ROICexc growth 3Y-19.14%
ROICexc growth 5Y-14.38%
OM growth 3Y-15.5%
OM growth 5Y-9.39%
PM growth 3Y-1.86%
PM growth 5Y1.44%
GM growth 3Y-1.62%
GM growth 5Y-0.73%
F-Score9
Asset Turnover0.35
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.3 | ||
| Debt/FCF | 3.29 | ||
| Debt/EBITDA | 1.43 | ||
| Cap/Depr | 50.23% | ||
| Cap/Sales | 5.23% | ||
| Interest Coverage | 8.96 | ||
| Cash Conversion | 59.86% | ||
| Profit Quality | 86.39% | ||
| Current Ratio | 1.36 | ||
| Quick Ratio | 0.99 | ||
| Altman-Z | 4.27 |
F-Score9
WACC7.48%
ROIC/WACC1.17
Cap/Depr(3y)52.98%
Cap/Depr(5y)82.03%
Cap/Sales(3y)5.99%
Cap/Sales(5y)6.61%
Profit Quality(3y)131.69%
Profit Quality(5y)119.05%
High Growth Momentum
Growth
EPS 1Y (TTM)18.57%
EPS 3Y-8.45%
EPS 5Y-0.86%
EPS Q2Q%84.08%
EPS Next Y48.96%
EPS Next 2Y37.44%
EPS Next 3Y34.53%
EPS Next 5Y26.6%
Revenue 1Y (TTM)17.14%
Revenue growth 3Y2.12%
Revenue growth 5Y4.6%
Sales Q2Q%26.21%
Revenue Next Year15.28%
Revenue Next 2Y14.13%
Revenue Next 3Y13.53%
Revenue Next 5Y10.98%
EBIT growth 1Y178.99%
EBIT growth 3Y-13.71%
EBIT growth 5Y-5.23%
EBIT Next Year142.1%
EBIT Next 3Y54.39%
EBIT Next 5Y34.43%
FCF growth 1Y106.74%
FCF growth 3Y-4.61%
FCF growth 5Y9.37%
OCF growth 1Y63.21%
OCF growth 3Y-7.18%
OCF growth 5Y7.09%